Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: India | Korea
Approved Indications: None
Known Adverse Events: None
Company: Yuekang Pharmaceutical Group Co., Ltd./Hefei Xinfeng Technology Development Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20132310 | N/A |
Completed |
Urinary Tract Infections|Urethritis|Escherichia coli Infections|Proteus Infections|Klebsiella Infections|Serratia Infections|Pseudomonas Infections|Cystitis |
2013-11-01 |